512 related articles for article (PubMed ID: 17550426)
1. Treatment with insulin glargine reduces asymptomatic hypoglycemia detected by continuous subcutaneous glucose monitoring in children and adolescents with type 1 diabetes.
Deiss D; Kordonouri O; Hartmann R; Hopfenmüller W; Lüpke K; Danne T
Pediatr Diabetes; 2007 Jun; 8(3):157-62. PubMed ID: 17550426
[TBL] [Abstract][Full Text] [Related]
2. Reduced hypoglycemic episodes and improved glycemic control in children with type 1 diabetes using insulin glargine and neutral protamine Hagedorn insulin.
Chase HP; Dixon B; Pearson J; Fiallo-Scharer R; Walravens P; Klingensmith G; Rewers M; Garg SK
J Pediatr; 2003 Dec; 143(6):737-40. PubMed ID: 14657818
[TBL] [Abstract][Full Text] [Related]
3. Glycemic patterns detected by continuous subcutaneous glucose sensing in children and adolescents with type 1 diabetes mellitus treated by multiple daily injections vs continuous subcutaneous insulin infusion.
Weintrob N; Schechter A; Benzaquen H; Shalitin S; Lilos P; Galatzer A; Phillip M
Arch Pediatr Adolesc Med; 2004 Jul; 158(7):677-84. PubMed ID: 15237068
[TBL] [Abstract][Full Text] [Related]
4. Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus.
Mullins P; Sharplin P; Yki-Jarvinen H; Riddle MC; Haring HU
Clin Ther; 2007 Aug; 29(8):1607-19. PubMed ID: 17919543
[TBL] [Abstract][Full Text] [Related]
5. A randomized trial comparing the rate of hypoglycemia--assessed using continuous glucose monitoring--in 125 preschool children with type 1 diabetes treated with insulin glargine or NPH insulin (the PRESCHOOL study).
Danne T; Philotheou A; Goldman D; Guo X; Ping L; Cali A; Johnston P
Pediatr Diabetes; 2013 Dec; 14(8):593-601. PubMed ID: 23730996
[TBL] [Abstract][Full Text] [Related]
6. Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study.
Bolli GB; Kerr D; Thomas R; Torlone E; Sola-Gazagnes A; Vitacolonna E; Selam JL; Home PD
Diabetes Care; 2009 Jul; 32(7):1170-6. PubMed ID: 19389820
[TBL] [Abstract][Full Text] [Related]
7. Insulin detemir improves glycemic control and reduces hypoglycemia in children with type 1 diabetes: findings from the Turkish cohort of the PREDICTIVE observational study.
Kurtoglu S; Atabek ME; Dizdarer C; Pirgon O; Isguven P; Emek S;
Pediatr Diabetes; 2009 Sep; 10(6):401-7. PubMed ID: 19220776
[TBL] [Abstract][Full Text] [Related]
8. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy.
Fulcher GR; Gilbert RE; Yue DK
Intern Med J; 2005 Sep; 35(9):536-42. PubMed ID: 16105155
[TBL] [Abstract][Full Text] [Related]
9. Continuous subcutaneous insulin infusion and multiple dose of insulin regimen display similar patterns of blood glucose excursions in pediatric type 1 diabetes.
Alemzadeh R; Palma-Sisto P; Parton EA; Holzum MK
Diabetes Technol Ther; 2005 Aug; 7(4):587-96. PubMed ID: 16120030
[TBL] [Abstract][Full Text] [Related]
10. Lower fasting blood glucose, glucose variability and nocturnal hypoglycaemia with glargine vs NPH basal insulin in subjects with Type 1 diabetes.
Bolli GB; Songini M; Trovati M; Del Prato S; Ghirlanda G; Cordera R; Trevisan R; Riccardi G; Noacco C
Nutr Metab Cardiovasc Dis; 2009 Oct; 19(8):571-9. PubMed ID: 18676131
[TBL] [Abstract][Full Text] [Related]
11. Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia.
Johansen OE; Vanberg PJ; Kilhovd BK; Jørgensen AP
Vasc Health Risk Manag; 2009; 5(1):121-8. PubMed ID: 19436668
[TBL] [Abstract][Full Text] [Related]
12. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial.
Esposito K; Ciotola M; Maiorino MI; Gualdiero R; Schisano B; Ceriello A; Beneduce F; Feola G; Giugliano D
Ann Intern Med; 2008 Oct; 149(8):531-9. PubMed ID: 18936501
[TBL] [Abstract][Full Text] [Related]
13. Insulin glargine versus intermediate-acting insulin as the basal component of multiple daily injection regimens for adolescents with type 1 diabetes mellitus.
Chase HP; Arslanian S; White NH; Tamborlane WV
J Pediatr; 2008 Oct; 153(4):547-53. PubMed ID: 18589448
[TBL] [Abstract][Full Text] [Related]
14. A1c, glucose variability and hypoglycemia risk in patients with type 1 diabetes.
Guelho D; Paiva I; Batista C; Barros L; Carrilho F
Minerva Endocrinol; 2014 Jun; 39(2):127-33. PubMed ID: 24736487
[TBL] [Abstract][Full Text] [Related]
15. Comparison of continuous blood glucose measurement with conventional documentation of hypoglycemia in patients with Type 2 diabetes on multiple daily insulin injection therapy.
Zick R; Petersen B; Richter M; Haug C;
Diabetes Technol Ther; 2007 Dec; 9(6):483-92. PubMed ID: 18034602
[TBL] [Abstract][Full Text] [Related]
16. Basal insulin switch from NPH to glargine in children and adolescents with type 1 diabetes.
Päivärinta M; Tapanainen P; Veijola R
Pediatr Diabetes; 2008 Jun; 9(3 Pt 2):83-90. PubMed ID: 18221431
[TBL] [Abstract][Full Text] [Related]
17. Comparison of breakfast and bedtime administration of insulin glargine in children and adolescents with Type 1 diabetes.
Karagüzel G; Satilmiş A; Akçurin S; Bircan I
Diabetes Res Clin Pract; 2006 Oct; 74(1):15-20. PubMed ID: 16621116
[TBL] [Abstract][Full Text] [Related]
18. Comparison of prandial AIR inhaled insulin alone to intensified insulin glargine alone and to AIR insulin plus intensified insulin glargine in patients with type 2 diabetes previously treated with once-daily insulin glargine.
Rosenstock J; Eliaschewitz FG; Heilmann CR; Muchmore DB; Hayes RP; Belin RM
Diabetes Technol Ther; 2009 Sep; 11 Suppl 2():S63-73. PubMed ID: 19772451
[TBL] [Abstract][Full Text] [Related]
19. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.
Yki-Järvinen H; Dressler A; Ziemen M;
Diabetes Care; 2000 Aug; 23(8):1130-6. PubMed ID: 10937510
[TBL] [Abstract][Full Text] [Related]
20. Effect of therapy with insulin glargine (lantus) on glycemic control in toddlers, children, and adolescents with diabetes.
Hathout EH; Fujishige L; Geach J; Ischandar M; Maruo S; Mace JW
Diabetes Technol Ther; 2003; 5(5):801-6. PubMed ID: 14633345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
